Physician profile
Mark E Gibbs
NPI 1619959004
$3,582.93
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,651 · 2021: $563.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $533.97 | 2019-2021 | |
| Pfizer INC. | $481.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $454.24 | 2019-2021 | |
| Novo Nordisk INC | $376.01 | 2019-2021 | |
| Amgen INC. | $204.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $193.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.86 | 2019-2021 | |
| Lilly USA, LLC | $170.27 | 2019-2021 | |
| Antares Pharma, INC. | $135.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $124.35 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.46 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $71.73 | 2019-2020 | |
| Abbvie INC. | $69.46 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $67.25 | 2019-2021 | |
| Esperion Therapeutics, INC. | $64.07 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.48 | 2020 | |
| Eisai INC. | $54.11 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $51.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.95 | 2019-2021 | |
| Genentech USA, INC. | $31.51 | 2019-2021 | |
| Shire North American Group INC | $27.33 | 2019 | |
| Mylan Specialty L.P. | $17.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.37 | 2020 | |
| Amarin Pharma, INC. | $16.18 | 2019 | |
| Vertiflex, INC. | $14.98 | 2019 | |
| Ucb, INC. | $14.68 | 2019 | |
| Strongbridge US INC. | $12.38 | 2019 | |
| Sanofi Pasteur INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.